GPT and inflammatory bowel disease: However, the phase 1 trial of SZN-1326 in inflammatory bowel disease (IBD) was suspended due to elevated liver enzymes (such as alanine transaminase and aspartate transaminase), which suggests that SZN-1326 may induce liver damage (Terry, 2022; Adisinsight, 2024).